Skip to main
  1. Stocks
  2. Roivant Sciences Ltd
  3. Forecast
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is attractive fundamentally because its first commercial asset is already validating demand: Lisraya generated $31.0M in net sales in its first five weeks after August approval, far above the $4.0M FactSet consensus, with “hundreds” of paid patients at quarter-end and many hundreds by the call. The company also showed improving operating leverage in 2Q27, reporting $35.1M of total revenue, a non-GAAP loss per share of $0.18 versus $0.41 expected, and $4.2B of cash, cash equivalents and marketable securities, which management believes is enough to reach profitability. Beyond the launch, the pipeline adds multiple shots on goal: mosliciguat’s Phase II PHocus data showed a 56.3% placebo-adjusted PVR reduction and brepocitinib’s broader program includes NIU and dermatomyositis, supporting durable long-term value.

Bears say

Roivant Sciences is weighed down by repeated pipeline disappointments, including the failure of IMVT assets in clinical trials for non-infectious uveitis and cutaneous sarcoidosis, as well as mosliciguat in PH-ILD, which weakens confidence in the company’s ability to convert its development portfolio into durable value. The outlook is further pressured by unanticipated safety issues with batoclimab, IMVT-1402, brepocitinib, and other pipeline assets, alongside litigation setbacks that can raise legal and operational risk and distract management from execution. With unaudited financial statements and additional R&D, regulatory, and commercial setbacks, the company appears exposed to heightened uncertainty across both its clinical pipeline and financial reporting.

ROIV has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

ROIV Analyst Forecast & Price Prediction

Get the latest ROIV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ROIV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Strong Buy based on their latest research and market trends.

According to 9 analysts, ROIV has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


ROIV Analyst Forecast & Price Prediction

Get the latest ROIV stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ROIV

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ROIV stock data and trends